20.500.12556/DiRROS-14389
Immunotherapy for metastatic non-small cell lung cancer : real-world data from an academic Central and Eastern European center
Background. Immunotherapy with immune checkpoint inhibitors (ICIs) recently became the standard treatment for patients with advanced non-small cell lung cancer (NSCLC). Here, we present the first results of a real-world observational study on the effectiveness of ICI monotherapy in patients with advanced NSCLC treated at a single academic center in a Central and Eastern European (CEE) country. Materials and methods. Overall, 66 consecutive patients with advanced NSCLC treated with ICIs in everyday clinical practice, either with first-line pembrolizumab (26 patients) or second-line atezolizumab, nivolumab, or pembrolizumab (40 patients), from August 2015 to November 2018, were included. All data were retrieved from a hospital lung cancer registry, in which the data is collected prospectively. Results. Included patients had a median age of 64 years, most were male (55%), 6% were in performance status >/=2, and 18% had controlled central nervous system metastases at baseline. In first-line, the median progression-free survival (mPFS) was 9.3 months, while the median overall survival (mOS) was not reached. The 1-year overall survival (OS) was 62%. In second-line, the mPFS and mOS were 3.5 months and 9.9 months, respectively, with a 1-year OS of 35%. In the overall population, adverse events of any grade were recorded in 79% of patients and of severe grade (3-4) in 12% of patients. Conclusion. The first real-world outcomes of NSCLC immunotherapy from a CEE country suggest comparable effectiveness to those observed in clinical trials and other real-world series, mainly coming from North America and Western European countries. Further data to inform on the real-world effectiveness of immunotherapy worldwide are needed.
non-small cell lung carcinoma
immunotherapy
advanced non-small cell lung cancer
real-world data
Central Europe
Europe
Eastern Europe
nedrobnocelični karcinom pljuč
imunoterapija
napredovali nedrobnocelinčni karcinom pljuč
podatki iz resničnega življenja
srednja Evropa
Evropa
vzhodna Evropa
true
false
true
AlphaMed Press
Angleški jezik
Ni določen
© 2021 Alpha Med Press
Neznano
2021-10-12 12:38:42
2021-10-12 12:38:44
2022-08-20 03:35:15
0000-00-00 00:00:00
2021
0
ZDA
0
Nasl. z nasl. zaslona;
Soavtorji: Lea Knez, Ana Herzog, Mile Kovačević, Tanja Čufer;
Opis vira z dne 17. 9. 2021;
str. 1-8
Vol. 26
2021
0000-00-00
PostprintKoncna
Objavljeno
NiDoloceno
0000-00-00
0000-00-00
0000-00-00
616-006
1549-490X
10.1002/onco.13909
76794115
https://theoncologist.onlinelibrary.wiley.com/doi/epdf/10.1002/onco.13909
1
https://dirros.openscience.si/Dokument.php?lang=slv&id=18174
Univerzitetna klinika za pljučne bolezni in alergijo Golnik
0
0
0